Prelude Therapeutics, Inc.

As of September 8, 2025, Prelude Therapeutics, Inc. shows a mildly bullish trend supported by positive MACD and moving averages, despite mixed signals from Bollinger Bands and underperformance compared to the S&P 500.

As of November 6, 2024, Prelude Therapeutics, Inc. is considered risky and overvalued due to negative financial metrics, including a Price to Book Value of 0.56 and significant declines in stock performance compared to the S&P 500.

As of November 6, 2024, Prelude Therapeutics, Inc. is considered a risky investment due to its negative financial metrics, including a Price to Book Value of 0.56, an EV to EBITDA ratio of 0.28, and a troubling Return on Equity of -123.89%, alongside a significant 78.01% decline in stock price over the past year.

As of June 17, 2025, the market trend is mildly bearish due to daily moving averages indicating bearish momentum, despite some mixed signals from weekly and monthly indicators.

As of March 2022, the management team of Prelude Therapeutics, Inc. is led by Mr. Kris Vaddi, who is the Chief Executive Officer, Founder, and Director.

Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on developing small molecule therapies for cancer. It has a market cap of $52.37 million and reported a net profit loss of $32 million as of March 2025.

As of Jun 18, Prelude Therapeutics, Inc. has a market capitalization of 52.37 million, with net sales of 7.00 million and a net profit of -127.83 million over the latest four quarters. The company reported shareholder's funds of 131.46 million and total assets of 175.51 million as of Dec 24.